Avax Technologies Inc – ‘8-K’ for 7/26/00

On:  Wednesday, 7/26/00, at 1:58pm ET   ·   For:  7/26/00   ·   Accession #:  912057-0-33222   ·   File #:  0-29222

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                         4     12K 
 2: EX-99.1     Miscellaneous Exhibit                                  2     15K 
 3: EX-99.2     Miscellaneous Exhibit                                  3     18K 

8-K   —   Current Report
Document Table of Contents

8-K
1st Page of 4
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
      SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
   ___________________________

  FORM 8-K

  CURRENT REPORT

  PURSUANT TO SECTION 13 OR 15(d) OF THE
 SECURITIES EXCHANGE ACT OF 1934

 JULY 26, 2000 (JULY 18, 2000)
Date of Report (Date of earliest event reported)

 AVAX TECHNOLOGIES, INC.
  (Exact name of Registrant as specified in its charter)

     DELAWARE                      000-29222              13-3575874
(State or other jurisdiction   (Commission File Number)       (IRS Employer   
     of incorporation)                                  Identification Number)

    4520 MAIN STREET
   SUITE 930
   KANSAS CITY, MO 64111
  (Address of principal executive offices)

  (816) 960-1333
    (Registrant's telephone number, including area code)

1 

8-K
2nd Page of 4
TOC
1st
Previous
Next
↓Bottom
Just 2nd
ITEM 5. OTHER EVENTS                                                            

(a)   M-VAX-TM- COMMERCIALLY AVAILABLE IN AUSTRALIA.            

  On July 18, 2000, the Company announced that M-Vax, its autologous
cell vaccine (AC Vaccine-TM-) for the treatment of stage 3 melanoma, is now     
commercially available in Australia. The Company currently owns a 65%           
interest in the Australian joint venture entity that is marketing M-Vax in      
Australia. M-Vax is produced in Australia through a contract manufacturing      
agreement with Bioenterprises Pty. Limited.                                     

      (b)   COMPANY SIGNS PRELIMINARY AGREEMENT TO ACQUIRE GENOPOIETIC S. A.

On July 18, 2000, the Company announced that it had signed an   
agreement to acquire Genopoietic S.A. and its corporate affiliates, based in    
Paris, France. The transaction is subject to certain closing conditions,        
which the parties anticipate will be completed by the end of the summer.        

Pursuant to the terms of the agreement, 100% of the outstanding 
shares of Genopoietic will be contributed to the Company in exchange for a      
combination of common stock of the Company and options to acquire common        
stock of the Company. In the aggregate, the shares of the Company's common      
stock and options to acquire common stock will not exceed 3,000,000 shares.     

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.                                      

EXHIBITS.                                                       

    99.1  Press Release dated July 18, 2000 announcing commercialization
of M-Vax in Australia.                              

99.2  Press Release dated July 18, 2000 announcing Company's    
agreement to acquire Genopoietic.                   

2 

8-K
3rd Page of 4
TOC
1st
Previous
Next
↓Bottom
Just 3rd
  SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the        
Company has duly caused this report to be signed on its behalf by the           
undersigned hereunto duly authorized.                                           

                     AVAX TECHNOLOGIES, INC.

Date:  July 26, 2000                                                            

                      By: /s/ David L. Tousley
                                 ---------------------------
                      Name:   David L. Tousley
                            Title: Chief Financial Officer

3 

8-K
Last Page of 4
TOC
1st
Previous
Next
↓Bottom
Just 4th
   EXHIBIT INDEX

Exhibit Number                            Description               
--------------                            -----------               
      99.1                     Press Release regarding commercialization
            of M-Vax in Australia.

99.2                     Press Release regarding Company's  
                       agreement to acquire Genopoietic.

4 

Dates Referenced Herein   and   Documents Incorporated by Reference

				Referenced-On Page
This ‘8-K’ Filing		Date		First		Last			Other Filings
Filed on / For Period End:		7/26/00		1		3			8-K
		7/18/00		1		2
									List all Filings